Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2017 / Cilt: 57 - Sayı: 3

Photodynamic Therapy Application In SKOV-3 Ovarian Cancer Cell Line

Skov-3 Over Kanseri Hücre Hattında Fotodinamik Terapi Uygulaması

Pages
119–124
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The IC50 value was determined to be 79 µM in the SKOV-3 ovarian cancer cell line.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is a leading cause of death of millions of people, in spite of countless studies and drugs developed.
📊
Key Findings & Data:PDT has been performed with a novel, water-soluble photosensitizer in the SKOV-3 ovarian cancer cell line.
💡
Conclusion & Impact:The IC50 value was determined to be 79 µM in the SKOV-3 ovarian cancer cell line.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cancer is a leading cause of death of millions of people, in spite of countless studies and drugs developed. Ovarian cancer is one of the deadliest cancer types, and it is the fifth most common in women. Despite the relatively better response to chemotherapy among treatment modalities, ovarian cancer still cannot be fully treated. For this reason, it is necessary to develop effective methods that are selective against cancer cells and/or to combine existing methods to develop original therapies that are free of the side effects of traditional treatment methods. Photodynamic therapy (PDT) involves a series of photochemical/photophysical reactions caused by the combination of a photosensitizer (a molecule activated by light), oxygen, and light of a specific wavelength, which leads to cell death. PDT has been performed with a novel, water-soluble photosensitizer in the SKOV-3 ovarian cancer cell line. While the photosensitizer did not show any toxicity up to a concentration of 100 µM, upon activation with light, significant toxicity was created via the generation of highly reactive oxygen species. The IC50 value was determined to be 79 µM in the SKOV-3 ovarian cancer cell line.

Özet

Sürdürülen sayısız araştırmaya ve geliştirilen ilaçlara rağmen günümüzde kanser hala milyonlarca insanın ölümüne neden olan hastalıkların başında gelmektedir. Over kanseri en ölümcül kanserlerden biri olup kadınlarda en çok görülen beşinci kanser türüdür. Uygulanan tedavi yöntemleri arasından kemoterapiye nispeten daha iyi yanıt alınmasına rağmen over kanseri halen tam olarak tedavi edilememektedir. Bu nedenle geleneksel tedavi yöntemlerinin ağır yan etkilerinden sıyrılmış, kanser hücresine karşı seçicilik gösteren etkili yöntemlerin geliştirilmesi ve/veya var olan yöntemlerin birleştirilerek özgün tedavilerin geliştirilmesi gerekmektedir. Fotodinamik terapi (FDT), ışıkla aktive olan molekül (fotosensitizer), oksijen ve uygun dalga boyundaki ışığın birleşmesi sonucu ortaya çıkan bir dizi fotokimyasal/fotofiziksel reaksiyonlar sonucu hücrenin ölümü prensibine dayanır. Özgün, suda çözünürlüğü yüksek fotosensitizerin SKOV-3 over kanser hattında FDT çalışmaları yapıldı. 100 µM konsantrasyona kadar karanlık toksisite görülmezken, aynı değerde ışıkla aktivasyonu sonucu fotosensitizerin reaktif oksijen türleri üreterek yüksek fototoksisiteye sebep olduğu görüldü. SKOV-3 over kanseri hücre hattında IC50 değeri 79 µM olarak belirlendi.

🔖

Cite This Article

ERDEM, S. S., PARLAR, R. E., ŞAHİN, U., OBEİDİN, V. A. (2022). Photodynamic Therapy Application In SKOV-3 Ovarian Cancer Cell Line. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 57 - Sayı: 3, 119–124. https://ajindex.com/articles/535249

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mir Y, Elrington SA, Hasan T. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomedicine 2013;9:1114-22
  2. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008;53:R61-109
  3. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005;4:283-93
  4. Yano S, Hirohara S, Obata M, Hagiya Y, Ogura SI, Ikeda A, et al. Current states and future views in photodynamic therapy. Journal of Photochemistry and Photobiology C: Photochemistry Reviews 2011;12:46-7
  5. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006;6:535-45
  6. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991;53:549-53
  7. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res 2006;12:5464-70
  8. DeLaney TF, Smith PD, Thomas GF, Tochner ZA, Sindelar WF, Pass HI, et al. A light-diffusing device for intraoperative photodynamic therapy in the peritoneal or pleural cavity. J Clin Laser Med Surg 1991;9:361-6
  9. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 2001;8:65-71
  10. Wierrani F, Fiedler D, Grin W, Henry M, Dienes E, Gharehbaghi K, et al. Clinical effect of meso-tetrahydroxyphenylchlorine based photodynamic therapy in recurrent carcinoma of the ovary: preliminary results. Br J Obstet Gynaecol 1997;104:376-8
  11. Goff BA, Blake J, Bamberg MP, Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer 1996;74:1194-8
  12. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271-7.